• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
2
Jun
2017

State AGs Pull Knives on Pharma, Grail Grows by Acquisition, CRISPR Jitters

/
Luke Timmerman
/
0
/
All
02 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Jun
2017

Atlas Venture Lures Rising Star Away from Polaris

/
Luke Timmerman
/
2
/
All, People, Venture Capital
01 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
31
May
2017

Parting Thoughts from Genzyme CEO David Meeker

/
Leora Schiff
/
0
/
All, People
31 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
May
2017

Alexion Expose, a Historic First at FDA, and Puma’s Come-From-Behind Victory

/
Luke Timmerman
/
0
/
All
26 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
May
2017

12 VCs Who Matter, But You Never Read About

/
Luke Timmerman
/
0
/
All, People, The Edge, Venture Capital
25 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
May
2017

A Biotech Pioneer Leaves Us, Verily Hires Ex-FDA Commish, Amazon Prowling Pharma

/
Luke Timmerman
/
0
/
All
19 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
May
2017

Former Sarepta CEO Gets $15M From Hedge Fund for Startup Incubator

/
Luke Timmerman
/
3
/
All
18 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
May
2017

A Former Lieutenant’s Tribute to Henri Termeer

/
Chris Rivera
/
1
/
All
18 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
May
2017

Biotech People Care, But How Can the Industry Make a Difference?

/
Luke Timmerman
/
0
/
All, The Edge
16 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
May
2017

Palpitations in PD-1/PD-L1 Land, a Mystery ALS Drug Approval, And a CAR-T Scare

/
Luke Timmerman
/
0
/
All
12 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
May
2017

Seattle Biotech: See You at the TR 2nd Anniversary Party Tuesday at Adaptive

/
Luke Timmerman
/
0
/
All
08 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
May
2017

House Passes Trumpcare, Alzheimer’s Drug Shenanigans, & An IPO Flurry

/
Luke Timmerman
/
0
/
All
05 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
May
2017

Who’s Doing What in Long-Read and Linked-Read DNA Sequencing

/
Luke Timmerman
/
0
/
All, The Edge
01 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
28
Apr
2017

Biotech Execs Going to White House, NASH Buzz, & Zuckerberg Bankrolls Preprint Movement

/
Luke Timmerman
/
0
/
All
28 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Apr
2017

David Baltimore on What it Takes to Create the Future

/
Luke Timmerman
/
0
/
All, People
24 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Apr
2017

Steve Holtzman on Why Biotech Should Stand Up for Science

/
Steve Holtzman
/
1
/
All, People, Politics
22 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Apr
2017

Verily, Verily Everywhere, Tesaro’s Cheaper PARP (Not Really), and a Juno Exec Shakeup

/
Luke Timmerman
/
0
/
All
21 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Apr
2017

Lessons from PCSK9, and How We Know Where to Go in Drug Discovery

/
Kyle Serikawa
/
0
/
All, Drugs, Science
20 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Apr
2017

Photos from the TR Anniversary Party and Boston Marathon

/
Luke Timmerman
/
0
/
All
19 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Apr
2017

It’s Time for a Human Knockout Project to Advance Drug Discovery

/
Robert Plenge
/
3
/
All, Drugs, Science
17 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 62 63 64 65 66 … 79 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder